ASXL1 and acute myeloid leukemia: Patients with DNMT3A, TET2, ASXL1, PHF6, or MLLPTD mutations who were in the WHO intermediate group had an adverse outcome compared to those with other genotypes [27]. DNMT3A mutation was found to be an adverse prognostic factor in cytogenetically normal AML with mutated NPM1 without FLT3ITD in terms of OS [41].